Robin Frye

2.1k total citations · 1 hit paper
19 papers, 1.6k citations indexed

About

Robin Frye is a scholar working on Molecular Biology, Pathology and Forensic Medicine and Dermatology. According to data from OpenAlex, Robin Frye has authored 19 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 7 papers in Pathology and Forensic Medicine and 7 papers in Dermatology. Recurrent topics in Robin Frye's work include Histone Deacetylase Inhibitors Research (15 papers), Lymphoma Diagnosis and Treatment (7 papers) and Cutaneous lymphoproliferative disorders research (7 papers). Robin Frye is often cited by papers focused on Histone Deacetylase Inhibitors Research (15 papers), Lymphoma Diagnosis and Treatment (7 papers) and Cutaneous lymphoproliferative disorders research (7 papers). Robin Frye collaborates with scholars based in United States, Australia and Italy. Robin Frye's co-authors include Richard Piekarz, Susan E. Bates, William D. Figg, Erin R. Gardner, Steven L. Allen, Maria L. Turner, Mark Kirschbaum, Seth M. Steinberg, Jasmine Zain and Elaine S. Jaffe and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Robin Frye

19 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

2009 561 citations Richard Piekarz, Robin Frye et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robin Frye United States	14	1.1k	474	441	362	329	19	1.6k
Asahi Ito Japan	20	543 0.5×	382 0.8×	170 0.4×	99 0.3×	556 1.7×	68	1.4k
Christian S. R. Hatton United Kingdom	10	1.7k 1.6×	194 0.4×	282 0.6×	66 0.2×	249 0.8×	14	2.2k
Andrea Lamprecht Austria	9	294 0.3×	347 0.7×	719 1.6×	172 0.5×	209 0.6×	14	1.1k
Lippman Sm United States	9	346 0.3×	221 0.5×	327 0.7×	130 0.4×	165 0.5×	16	807
Stanley Frankel United States	13	514 0.5×	424 0.9×	362 0.8×	48 0.1×	196 0.6×	24	1.2k
John L. Langowski United States	9	279 0.3×	628 1.3×	232 0.5×	91 0.3×	849 2.6×	20	1.3k
Georgios Z. Rassidakis United States	17	489 0.4×	414 0.9×	375 0.9×	54 0.1×	234 0.7×	34	1.0k
Todd Covey United States	14	318 0.3×	301 0.6×	487 1.1×	93 0.3×	663 2.0×	33	1.4k
Diane Lejeune Belgium	9	379 0.3×	554 1.2×	159 0.4×	148 0.4×	1.0k 3.1×	9	1.4k
Margarete Zaborski Germany	20	660 0.6×	306 0.6×	141 0.3×	138 0.4×	302 0.9×	43	1.5k

Countries citing papers authored by Robin Frye

Since Specialization

Citations

This map shows the geographic impact of Robin Frye's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robin Frye with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robin Frye more than expected).

Fields of papers citing papers by Robin Frye

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robin Frye. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robin Frye. The network helps show where Robin Frye may publish in the future.

Co-authorship network of co-authors of Robin Frye

This figure shows the co-authorship network connecting the top 25 collaborators of Robin Frye. A scholar is included among the top collaborators of Robin Frye based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robin Frye. Robin Frye is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Amiri‐Kordestani, Laleh, Victoria Luchenko, Cody J. Peer, et al.. (2013). Phase I Trial of a New Schedule of Romidepsin in Patients with Advanced Cancers. Clinical Cancer Research. 19(16). 4499–4507. 57 indexed citations

Frye, Robin, et al.. (2012). Romidepsin: A New Drug for the Treatment of Cutaneous T-Cell Lymphoma. Clinical journal of oncology nursing. 16(2). 195–204. 45 indexed citations

Akilov, Oleg E., Clíona Grant, Robin Frye, et al.. (2012). Low-dose electron beam radiation and romidepsin therapy for symptomatic cutaneous T-cell lymphoma lesions. British Journal of Dermatology. 167(1). 194–197. 26 indexed citations

Piekarz, Richard, Robin Frye, H. Miles Prince, et al.. (2011). Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood. 117(22). 5827–5834. 359 indexed citations

Grant, Clíona, Richard Piekarz, Cody J. Peer, et al.. (2010). Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. Expert Review of Anticancer Therapy. 10(7). 997–1008. 224 indexed citations

Bates, Susan E., Zhirong Zhan, Kenneth Steadman, et al.. (2009). Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T‐cell lymphoma. British Journal of Haematology. 148(2). 256–267. 64 indexed citations

Piekarz, Richard, John C. Wright, Robin Frye, et al.. (2009). Final Results of a Phase 2 NCI Multicenter Study of Romidepsin in Patients with Relapsed Peripheral T-Cell Lymphoma (PTCL).. Blood. 114(22). 1657–1657. 11 indexed citations

Piekarz, Richard, Robin Frye, Maria L. Turner, et al.. (2009). Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma. Journal of Clinical Oncology. 27(32). 5410–5417. 561 indexed citations breakdown →

Woo, Sukyung, Erin R. Gardner, Xiaohong Chen, et al.. (2009). Population Pharmacokinetics of Romidepsin in Patients with Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma. Clinical Cancer Research. 15(4). 1496–1503. 53 indexed citations

10.

Piekarz, Richard, Erin R. Gardner, Zhirong Zhan, et al.. (2008). Pharmacokinetic and biomarker analysis in a phase II trial of the HDAC inhibitor romidepsin, FK228. Cancer Research. 68. 5831–5831. 1 indexed citations

11.

Piekarz, Richard, James R. Wright, Robin Frye, et al.. (2008). Results of a Phase 2 NCI Multicenter Study of Romidepsin in Patients with Relapsed Peripheral T-Cell Lymphoma (PTCL).. Blood. 112(11). 1567–1567. 31 indexed citations

12.

Bates, Susan E., Richard Piekarz, James R. Wright, et al.. (2008). Final Clinical Results of a Phase 2 NCI Multicenter Study of Romidepsin in Recurrent Cutaneous T-Cell Lymphoma (Molecular Analyses Included).. Blood. 112(11). 1568–1568. 16 indexed citations

13.

Piekarz, Richard, Robin Frye, John J. Wright, et al.. (2007). Update of the NCI multiinstitutional phase II trial of romidepsin, FK228, for patients with cutaneous or peripheral T-cell lymphoma. Journal of Clinical Oncology. 25(18_suppl). 8027–8027. 28 indexed citations

14.

Piekarz, Richard, Robin Frye, Maria L. Turner, et al.. (2006). Phase II Trial of Romidepsin, FK228, in Cutaneous and Peripheral T-Cell Lymphoma: Clinical Activity and Molecular Markers.. Blood. 108(11). 2469–2469. 7 indexed citations

15.

Piekarz, Richard, Robin Frye, Maria L. Turner, et al.. (2005). Completion of the First Cohort of Patients with Cutaneous T-Cell Lymphoma Enrolled on a Phase II Trial of Depsipeptide.. Blood. 106(11). 231–231. 17 indexed citations

16.

Piekarz, Richard, Robin Frye, Maria L. Turner, et al.. (2005). Responses and molecular markers in patients with peripheral T-cell lymphoma treated on a phase II trial of depsipeptide, FK228. Journal of Clinical Oncology. 23(16_suppl). 3061–3061. 13 indexed citations

17.

Piekarz, Richard, et al.. (2004). Update on the phase II trial and correlative studies of depsipeptide in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Journal of Clinical Oncology. 22(14_suppl). 3028–3028. 6 indexed citations

18.

Piekarz, Richard, Robin Frye, Maria L. Turner, et al.. (2004). Update on the phase II trial and correlative studies of depsipeptide in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Journal of Clinical Oncology. 22(14_suppl). 3028–3028. 9 indexed citations

19.

Mulshine, James L., Jane C. Atkinson, Robert O. Greer, et al.. (2004). Randomized, Double-Blind, Placebo-Controlled Phase IIB Trial of the Cyclooxygenase Inhibitor Ketorolac as an Oral Rinse in Oropharyngeal Leukoplakia. Clinical Cancer Research. 10(5). 1565–1573. 74 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact